356 related articles for article (PubMed ID: 20739454)
1. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis for histone acetylation of human colon cancer cells treated with a novel HDAC inhibitor.
Zhao Y; Fang X; Wang Y; Zhang J; Jiang S; Liu Z; Ma Z; Xu L; Li E; Zhang K
Curr Pharm Des; 2014; 20(11):1866-73. PubMed ID: 23888955
[TBL] [Abstract][Full Text] [Related]
3. Largazole: from discovery to broad-spectrum therapy.
Hong J; Luesch H
Nat Prod Rep; 2012 Apr; 29(4):449-56. PubMed ID: 22334030
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
Pilon JL; Clausen DJ; Hansen RJ; Lunghofer PJ; Charles B; Rose BJ; Thamm DH; Gustafson DL; Bradner JE; Williams RM
Cancer Chemother Pharmacol; 2015 Apr; 75(4):671-82. PubMed ID: 25616967
[TBL] [Abstract][Full Text] [Related]
5. Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole.
Zhang B; Ruan ZW; Luo D; Zhu Y; Ding T; Sui Q; Lei X
Mar Drugs; 2020 Jun; 18(7):. PubMed ID: 32629787
[TBL] [Abstract][Full Text] [Related]
6. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Ying Y; Taori K; Kim H; Hong J; Luesch H
J Am Chem Soc; 2008 Jul; 130(26):8455-9. PubMed ID: 18507379
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of largazole zinc-binding group analogs.
Kim B; Ratnayake R; Lee H; Shi G; Zeller SL; Li C; Luesch H; Hong J
Bioorg Med Chem; 2017 Jun; 25(12):3077-3086. PubMed ID: 28416100
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.
Cole KE; Dowling DP; Boone MA; Phillips AJ; Christianson DW
J Am Chem Soc; 2011 Aug; 133(32):12474-7. PubMed ID: 21790156
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
Bowers A; West N; Taunton J; Schreiber SL; Bradner JE; Williams RM
J Am Chem Soc; 2008 Aug; 130(33):11219-22. PubMed ID: 18642817
[TBL] [Abstract][Full Text] [Related]
12. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups.
Bhansali P; Hanigan CL; Perera L; Casero RA; Tillekeratne LM
Eur J Med Chem; 2014 Oct; 86():528-41. PubMed ID: 25203782
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
15. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8.
Decroos C; Clausen DJ; Haines BE; Wiest O; Williams RM; Christianson DW
Biochemistry; 2015 Mar; 54(12):2126-35. PubMed ID: 25793284
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs.
Guerra-Bubb JM; Bowers AA; Smith WB; Paranal R; Estiu G; Wiest O; Bradner JE; Williams RM
Bioorg Med Chem Lett; 2013 Nov; 23(21):6025-8. PubMed ID: 24035339
[TBL] [Abstract][Full Text] [Related]
17. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
Pojani E; Barlocco D
Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
[TBL] [Abstract][Full Text] [Related]
19. Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors.
Li S; Yao H; Xu J; Jiang S
Molecules; 2011 Jun; 16(6):4681-94. PubMed ID: 21654576
[TBL] [Abstract][Full Text] [Related]
20. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.
Bhansali P; Hanigan CL; Casero RA; Tillekeratne LM
J Med Chem; 2011 Nov; 54(21):7453-63. PubMed ID: 21936551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
